Cargando…

Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models

Intracerebral hemorrhage is a fatal subtype of stroke, with crucial impact on public health. Surgical removal of the hematoma as an early-stage treatment for ICH can’t improve long-term prognosis remarkably. Liangxue tongyu prescription (LP), a Traditional Chinese Medicine (TCM) formula, includes ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xun, Huang, Xi, Tang, Yuanlin, Zhao, Fangli, Cao, Yanmei, Yin, Lian, Li, Guochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232344/
https://www.ncbi.nlm.nih.gov/pubmed/30459599
http://dx.doi.org/10.3389/fphar.2018.01169
_version_ 1783370386588565504
author Li, Xun
Huang, Xi
Tang, Yuanlin
Zhao, Fangli
Cao, Yanmei
Yin, Lian
Li, Guochun
author_facet Li, Xun
Huang, Xi
Tang, Yuanlin
Zhao, Fangli
Cao, Yanmei
Yin, Lian
Li, Guochun
author_sort Li, Xun
collection PubMed
description Intracerebral hemorrhage is a fatal subtype of stroke, with crucial impact on public health. Surgical removal of the hematoma as an early-stage treatment for ICH can’t improve long-term prognosis remarkably. Liangxue tongyu prescription (LP), a Traditional Chinese Medicine (TCM) formula, includes eight ingredients and has been used to treat ICH in the clinical. In the study, we elucidated the pharmacological efficacy and therapeutic efficacy of LP to dissect the mechanism of LP against ICH via network analysis and experimental validation. First, we discovered 34 potential compounds and 146 corresponding targets in LP based on network prediction. 24 signal pathway were obtained by the Clue Go assay based on potential compounds in LP against ICH. Second, we found that LP can not only decreased the level of high sensitive C reactive protein (HS-CRP), tumor necrosis factor-α (TNF-α), NF-kβ, D-dimmer (D2D), estradiol (E2), S-100B, neuron specific enolase (NSE), and interleukin 1 (IL-1) in plasma on spontaneously hypertensive rats (SHRs), but also promoted cell proliferation and inhibited cell apoptosis on the glutamate-induced PC12 cell. The compounds including Taurine, Paeonol, and Ginsenoside Rb1 in LP can activate PI3K/AKT pathway. Third, from the three-factor two-level factorial design, compound combinations in LP, such as Taurine and Paeonol, Taurine and Geniposide, Ginsenoside Rg1, and Ginsenoside Rb1, had first-level interactions on cell proliferation. Compound combinations including Taurine and Paeonol, Ginsenoside Rg1 and Ginsenoside Rb1 had as significant increase in efficiency on inhibiting the apoptosis of PC12 cells at the low concentration and up-regulating of PI3K and AKT. Overall, our results suggested that LP had integrated therapeutic effect on ICH due to activities of anti-inflammatory, anti-coagulation, blood vessel protection, and protection neuron from excitotoxicity based on the way of “multi-component, multi-target, multi-pathway,” and compound combination in LP can offer protection neuron from excitotoxicity at the low concentration by activation of the PI3K/Akt signal pathway.
format Online
Article
Text
id pubmed-6232344
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62323442018-11-20 Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models Li, Xun Huang, Xi Tang, Yuanlin Zhao, Fangli Cao, Yanmei Yin, Lian Li, Guochun Front Pharmacol Pharmacology Intracerebral hemorrhage is a fatal subtype of stroke, with crucial impact on public health. Surgical removal of the hematoma as an early-stage treatment for ICH can’t improve long-term prognosis remarkably. Liangxue tongyu prescription (LP), a Traditional Chinese Medicine (TCM) formula, includes eight ingredients and has been used to treat ICH in the clinical. In the study, we elucidated the pharmacological efficacy and therapeutic efficacy of LP to dissect the mechanism of LP against ICH via network analysis and experimental validation. First, we discovered 34 potential compounds and 146 corresponding targets in LP based on network prediction. 24 signal pathway were obtained by the Clue Go assay based on potential compounds in LP against ICH. Second, we found that LP can not only decreased the level of high sensitive C reactive protein (HS-CRP), tumor necrosis factor-α (TNF-α), NF-kβ, D-dimmer (D2D), estradiol (E2), S-100B, neuron specific enolase (NSE), and interleukin 1 (IL-1) in plasma on spontaneously hypertensive rats (SHRs), but also promoted cell proliferation and inhibited cell apoptosis on the glutamate-induced PC12 cell. The compounds including Taurine, Paeonol, and Ginsenoside Rb1 in LP can activate PI3K/AKT pathway. Third, from the three-factor two-level factorial design, compound combinations in LP, such as Taurine and Paeonol, Taurine and Geniposide, Ginsenoside Rg1, and Ginsenoside Rb1, had first-level interactions on cell proliferation. Compound combinations including Taurine and Paeonol, Ginsenoside Rg1 and Ginsenoside Rb1 had as significant increase in efficiency on inhibiting the apoptosis of PC12 cells at the low concentration and up-regulating of PI3K and AKT. Overall, our results suggested that LP had integrated therapeutic effect on ICH due to activities of anti-inflammatory, anti-coagulation, blood vessel protection, and protection neuron from excitotoxicity based on the way of “multi-component, multi-target, multi-pathway,” and compound combination in LP can offer protection neuron from excitotoxicity at the low concentration by activation of the PI3K/Akt signal pathway. Frontiers Media S.A. 2018-11-06 /pmc/articles/PMC6232344/ /pubmed/30459599 http://dx.doi.org/10.3389/fphar.2018.01169 Text en Copyright © 2018 Li, Huang, Tang, Zhao, Cao, Yin and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Xun
Huang, Xi
Tang, Yuanlin
Zhao, Fangli
Cao, Yanmei
Yin, Lian
Li, Guochun
Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title_full Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title_fullStr Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title_full_unstemmed Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title_short Assessing the Pharmacological and Therapeutic Efficacy of Traditional Chinese Medicine Liangxue Tongyu Prescription for Intracerebral Hemorrhagic Stroke in Neurological Disease Models
title_sort assessing the pharmacological and therapeutic efficacy of traditional chinese medicine liangxue tongyu prescription for intracerebral hemorrhagic stroke in neurological disease models
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232344/
https://www.ncbi.nlm.nih.gov/pubmed/30459599
http://dx.doi.org/10.3389/fphar.2018.01169
work_keys_str_mv AT lixun assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT huangxi assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT tangyuanlin assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT zhaofangli assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT caoyanmei assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT yinlian assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels
AT liguochun assessingthepharmacologicalandtherapeuticefficacyoftraditionalchinesemedicineliangxuetongyuprescriptionforintracerebralhemorrhagicstrokeinneurologicaldiseasemodels